Preliminary phase III findings support using ponatinib, a third-generation tyrosine kinase inhibitor, as part of standard care for adults newly diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia. In the PhALLCON trial, ponatinib significantly outperformed imatinib, inducing deeper and more durable responses with no added toxicity.

You do not currently have access to this content.